Baird analyst Catherine Ramsey Schulte maintained an Outperform rating and $24 price target on Natera, saying she continues to recommend Natera as a top idea following recent investor meetings with CEO Steve Chapman and CFO Mike Brophy. The analyst thinks Natera’s core business is healthy and believes transplant and oncology opportunities are only partially valued in the stock today and could drive meaningful upside over the next few years.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.